The underlying pathogenesis of BPD is thought to be due to disruption of normal growth and vasculogenesis in the saccular stage of lung development

May 16, 2017

is expressed as the percent of the total lymph node area; p,0.01 compared with the PBS-LIP-treated group. Effect of Cl2MDP-LIP on angiogenesis, lymphangiogenesis, and macrophage and neutrophil infiltration by LNM35 tumors. IHC analysis was performed on day 35 using specific antibodies for vascular endothelium, lymphatic vessels, infiltrated macrophages, and infiltrated neutrophils. Five areas of each tumor section from five tumor samples were quantitatively analyzed; p,0.01. Effect of Cl2MDP-LIP on the expression of mouse VEGF-A, VEGF-C, and VEGF-D mRNA in LNM35 tumors, determined by qRT-PCR analysis of five tumors on day 35; p,0.05 compared with the PBS-LIP-treated group. doi:10.1371/journal.pone.0099568.g003 and -D) in cancer cells and/or tumor stromal macrophages in lower and highly metastatic tumors. As shown in indicating that Cl2MDP-LIP suppressed VEGF-A, VEGF-C, and VEGF-D expression by TAMs. Macrophages recruited and activated by cancer cells in vivo acquire M2-type characteristics and express VEGF-A and VEGF-C through IL-1/IL-1R signaling Because IL-1a expression was augmented in the highly metastatic cancer cells and tumors, we examined whether IL-1/IL-1R signaling was involved in the high angiogenic and lymphangiogenic potential of LNM35 tumors. Matrigel plugs containing human lung cancer cells with or without 22441874 the IL-1R antagonist anakinra were subcutaneously implanted in mice. The deeper red color of the untreated LNM35 plugs compared with the anakinra-treated LNM35 plugs and all of the N15 plugs suggested more intense angiogenesis through IL-1/IL-1R signaling promotion. Higher microvascular and lymphatic vessel densities as well as larger numbers of infiltrating macrophages were found in LNM35 plugs compared with N15 plugs with or without anakinra treatment. Consistent with these observations, treatment with the IL-1R antagonist significantly suppressed lymphangiogenesis, angiogenesis, and macrophage infiltration in the LNM35 plugs. Co-immunostaining of these plugs for the macrophage marker F4/80 and lymphatic vessel marker AG1024 site LYVE-1 demonstrated that the LYVE-1+ cells were lymphatic vessels and not LYVE1+ macrophages. IHC staining for another lymphatic vessel marker, podoplanin, 17594192 confirmed the presence of more intense lymphangiogenesis in the LNM35 plugs. To characterize the macrophages recruited and activated by cancer cells to promote angiogenesis and lymphangiogenesis, we performed experiments using Matrigel plugs containing human lung cancer cells in the presence or absence of anakinra. Macrophages that accumulated in LNM35 plugs expressed relatively higher levels of VEGF-A and VEGF-C than those that accumulated in N15 plugs with or without anakinra. Anakinra markedly blocked VEGF-A and VEGF-C expression in the macrophages in the LNM35 plugs. Furthermore, the expression of arginase and IL-10 was higher and that of iNOS and IL-12 was lower in TAMs in the LNM35 plugs, but not in those in the N15 plugs, suggesting that the macrophages recruited by LNM35 cells are mainly of the M2 type. Anakinra treatment of the LNM35 plugs increased the expression of iNOS and IL-12 and decreased the expression of arginase in macrophages, suggesting a critical role for IL-1/IL-1R signaling in M2-type macrophage accumulation. The more abundant VEGF-A and VEGF-C expression in LNM35 TAMs indicates that these M2-type macrophages are highly angiogenic and lymphangiogenic. To characterize the macrophages recruited and activated by highly aggressive